PhoenixBio Co.,Ltd. Logo

PhoenixBio Co.,Ltd.

A CRO providing humanized liver mouse models for preclinical drug studies.

6190 | T

Overview

Corporate Details

ISIN(s):
JP3803010002
LEI:
Country:
Japan
Address:
東広島市鏡山三丁目4番1号

Description

PhoenixBio is a contract research organization (CRO) specializing in translational animal models for the pharmaceutical industry. The company's core product is the PXB-mouse®, a proprietary chimeric mouse model featuring a liver that is highly repopulated (over 70%) with functional human hepatocytes. This humanized liver model is utilized globally in preclinical studies to evaluate drug metabolism, pharmacokinetics, and toxicity. In addition to supplying the PXB-mouse® and primary human hepatocytes (PXB-cells®), PhoenixBio provides comprehensive, quality-controlled contract study services to support drug discovery and early development projects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:12
確認書
Japanese 8.1 KB
2025-11-14 08:10
半期報告書-第25期(2025/04/01-2026/03/31)
Japanese 163.4 KB
2025-07-01 04:29
臨時報告書
Japanese 22.2 KB
2025-06-25 04:07
内部統制報告書-第24期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-25 04:04
確認書
Japanese 8.0 KB
2025-06-25 04:02
有価証券報告書-第24期(2024/04/01-2025/03/31)
Japanese 912.3 KB
2025-05-23 05:02
臨時報告書
Japanese 19.1 KB
2025-05-14 09:55
臨時報告書
Japanese 20.1 KB
2025-03-03 02:24
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
確認書
Japanese 8.0 KB
2024-11-14 08:04
半期報告書-第24期(2024/04/01-2025/03/31)
Japanese 165.5 KB
2024-07-02 02:35
臨時報告書
Japanese 18.4 KB
2024-07-01 07:59
臨時報告書
Japanese 21.4 KB
2024-06-27 03:06
内部統制報告書-第23期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-27 03:04
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all PhoenixBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PhoenixBio Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PhoenixBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT
Adeia Inc. Logo
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires, develops, and deploys health technologies to address major health challenges.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochip diagnostic systems for precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
United States of America
ALGS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.